NASDAQ:TLC TAIWAN LIPOSOME/S Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TAIWAN LIPOSOME/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.70 -0.02 (-0.42 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$4.53Now: $4.70▼$4.8050-Day Range$4.33MA: $5.01▼$7.1252-Week Range$2.48Now: $4.70▼$12.65Volume15,351 shsAverage Volume97,396 shsMarket Capitalization$174.36 millionP/E RatioN/ADividend YieldN/ABeta1.17 ProfileAnalyst RatingsChartCompetitorsEarningsInstitutional OwnershipHeadlinesShort InterestSocial Media Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site. The company provides various product candidates that target various areas of unmet medical need in pain management, ophthalmology, and oncology. Its lead product candidate is TLC599, is an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP) that is in Phase II clinical trials for knee osteoarthritis pain. The company's product candidates also comprises TLC399, BioSeizer formulation of DSP intended as an intravitreal injection for the treatment of macular edema due to retinal vein occlusion; TLC590, a non-opioid anesthetic for post-surgical pain management; and TLC178, an API to treat rhabdomyosarcoma. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei City, Taiwan with offices in Hsinchu, Hong Kong, Leiden, Melbourne, Shanghai, South San Francisco, and Tokyo.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingTAIWAN LIPOSOME/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.50, TAIWAN LIPOSOME/S has a forecasted upside of 144.7% from its current price of $4.70.Amount of Analyst CoverageTAIWAN LIPOSOME/S has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesTAIWAN LIPOSOME/S has received 67 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTAIWAN LIPOSOME/S has received 65 “underperform” votes. (Add your “underperform” vote.)Community SentimentTAIWAN LIPOSOME/S has received 50.76% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about TAIWAN LIPOSOME/S and other stocks. Vote “Outperform” if you believe TLC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TLC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTAIWAN LIPOSOME/S does not currently pay a dividend.Dividend GrowthTAIWAN LIPOSOME/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TAIWAN LIPOSOME/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.26% of the stock of TAIWAN LIPOSOME/S is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for TAIWAN LIPOSOME/S are expected to decrease in the coming year, from ($0.83) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TAIWAN LIPOSOME/S is -6.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TAIWAN LIPOSOME/S is -6.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTAIWAN LIPOSOME/S has a P/B Ratio of 7.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.20 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TLC Previous Symbol CUSIPN/A CIKN/A Webwww.tlcbio.com Phone886-2-2655-7377Debt Debt-to-Equity Ratio0.53 Current Ratio5.83 Quick Ratio5.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.99 million Price / Sales24.94 Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book7.23Profitability EPS (Most Recent Fiscal Year)($0.82) Net Income$-27,000,000.00 Net Margins-1,514.38% Return on Equity-129.25% Return on Assets-66.73%Miscellaneous EmployeesN/A Outstanding Shares37,097,000Market Cap$174.36 million Next Earnings Date10/27/2020 (Estimated) OptionableNot Optionable $4.70 -0.02 (-0.42 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive TLC News and Ratings via Email Sign-up to receive the latest news and ratings for TLC and its competitors with MarketBeat's FREE daily newsletter. TAIWAN LIPOSOME/S (NASDAQ:TLC) Frequently Asked Questions How has TAIWAN LIPOSOME/S's stock been impacted by Coronavirus (COVID-19)? TAIWAN LIPOSOME/S's stock was trading at $3.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TLC shares have increased by 22.1% and is now trading at $4.70. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of TAIWAN LIPOSOME/S? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TAIWAN LIPOSOME/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TAIWAN LIPOSOME/S. When is TAIWAN LIPOSOME/S's next earnings date? TAIWAN LIPOSOME/S is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020. View our earnings forecast for TAIWAN LIPOSOME/S. How were TAIWAN LIPOSOME/S's earnings last quarter? TAIWAN LIPOSOME/S (NASDAQ:TLC) posted its earnings results on Wednesday, August, 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.13. The company had revenue of $0.40 million for the quarter. TAIWAN LIPOSOME/S had a negative return on equity of 129.25% and a negative net margin of 1,514.38%. View TAIWAN LIPOSOME/S's earnings history. What price target have analysts set for TLC? 2 brokerages have issued 1 year price objectives for TAIWAN LIPOSOME/S's stock. Their forecasts range from $11.00 to $12.00. On average, they expect TAIWAN LIPOSOME/S's share price to reach $11.50 in the next twelve months. This suggests a possible upside of 144.7% from the stock's current price. View analysts' price targets for TAIWAN LIPOSOME/S. Who are some of TAIWAN LIPOSOME/S's key competitors? Some companies that are related to TAIWAN LIPOSOME/S include Endo International (ENDP), RAPT Therapeutics (RAPT), VBI Vaccines (VBIV), Emisphere Technologies (EMIS), Provention Bio (PRVB), Kadmon (KDMN), Cara Therapeutics (CARA), Spectrum Pharmaceuticals (SPPI), DiaMedica Therapeutics (DMCAF), Collegium Pharmaceutical (COLL), ImmunoGen (IMGN), Northwest Biotherapeutics (NWBO), Basilea Pharmaceutica (BPMUF), ORIC Pharmaceuticals (ORIC) and Eagle Pharmaceuticals (EGRX). View all competitors. What other stocks do shareholders of TAIWAN LIPOSOME/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other TAIWAN LIPOSOME/S investors own include Gilead Sciences (GILD), Wells Fargo & Company (WFC), IBM (IBM), Pfizer (PFE), AbbVie (ABBV), Agnico Eagle Mines (AEM), Applied Genetic Technologies (AGTC), Franklin Resources (BEN), Bank of Nova Scotia (BNS) and Celldex Therapeutics (CLDX). Who are TAIWAN LIPOSOME/S's key executives? TAIWAN LIPOSOME/S's management team includes the following people: Dr. Keelung Hong, Founder, Chairman & CEO (Age 75)Mr. Zhi-Hong Yeh M.B.A., Pres & GM (Age 46)Ms. Ru-Yun Lin M.B.A., CFO and VP of Fin. & Admin. (Age 53)Dr. Wenji Chen M.B.A., Ph.D., VP of Corp. Devel. Division (Age 59)Dr. Luke Guo Ph.D., Chief Scientific Advisor & Member of Scientific Advisory Board When did TAIWAN LIPOSOME/S IPO? (TLC) raised $29 million in an IPO on the week of November 19th 2018. The company issued 5,000,000 shares at a price of $5.80 per share. Cantor served as the underwriter for the IPO and CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw & Company (UK) Ltd. were co-managers. What is TAIWAN LIPOSOME/S's stock symbol? TAIWAN LIPOSOME/S trades on the NASDAQ under the ticker symbol "TLC." How do I buy shares of TAIWAN LIPOSOME/S? Shares of TLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is TAIWAN LIPOSOME/S's stock price today? One share of TLC stock can currently be purchased for approximately $4.70. How big of a company is TAIWAN LIPOSOME/S? TAIWAN LIPOSOME/S has a market capitalization of $174.36 million and generates $6.99 million in revenue each year. The company earns $-27,000,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. What is TAIWAN LIPOSOME/S's official website? The official website for TAIWAN LIPOSOME/S is www.tlcbio.com. How can I contact TAIWAN LIPOSOME/S? TAIWAN LIPOSOME/S's mailing address is 11TH FLOOR-1 YUANQU STREET NANGANG DISTRICT, TAIPEI CITY F5, 11503. The company can be reached via phone at 886-2-2655-7377 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
